STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
IPO Year:
Exchange: NASDAQ
Website: staar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2025 | $17.00 | Equal Weight | Wells Fargo |
| 2/12/2025 | Buy → Hold | Jefferies | |
| 2/12/2025 | $45.00 → $17.00 | Outperform → Neutral | Mizuho |
| 2/12/2025 | Buy → Neutral | BTIG Research | |
| 2/12/2025 | Outperform → Mkt Perform | William Blair | |
| 7/15/2024 | $50.00 → $37.00 | Equal-Weight → Underweight | Morgan Stanley |
| 6/11/2024 | $46.00 | Neutral → Buy | BTIG Research |
| 3/11/2024 | $30.00 → $50.00 | Hold → Buy | Stifel |
| 12/5/2023 | Buy → Hold | Needham | |
| 12/4/2023 | $35.00 | Equal-Weight | Morgan Stanley |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
DFAN14A - STAAR SURGICAL CO (0000718937) (Subject)
DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
10-Q - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)
DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)
DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)
Fastest customizable press release news feed in the world
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha
30-Day Go-Shop Period to Actively Solicit Other Third-Party Proposals No Termination Fee Payable to Alcon if STAAR Terminates Merger Agreement to Accept a Superior Proposal from a Qualified Bidder Alcon Waives All Matching Rights for Third-Party Proposals Alcon Waives Information Rights During the Go Shop Period Alcon to Engage with STAAR Stockholders to Solicit Support in Favor of the Merger Proposal STAAR Special Meeting of Stockholders Postponed to December 19, 2025 to Provide Time for Third-Party Proposals STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that
Performance Reflects Strong ICL Demand and Validates Shareholder Opposition to the Proposed Merger Deferring to Alcon to Solicit Proxies for the Proposed Merger Will Not Relieve STAAR's Board of Its Credibility Deficit with Shareholders Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today released the following letter to the Board of Directors of STAAR after reviewing STAAR's third quarter earnings press release and Alcon Inc.'s (SIX/NYSE:ALC) November 4, 2025 investor presentation. The text of the letter to the Board is a
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025. Third Quarter 2025 Financial Overview Net sales of $94.7 million up 6.9% Y/Y Net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment that was subject to extended payment terms, and which was paid in full during the third quarter 2025 pursuant to such payment terms (the "December China Shipment") Net sales excluding China of $38.9 million up 7.7% Y/Y Gross margin at 82.2% vs. 77.3% year ago due to the timing of the reco
Reminds STAAR's Board That It Does Not Need Alcon's Permission to Remain Independent or Run a Proper Strategic Alternatives Process Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today commented on the investor presentation issued by Alcon Inc. ("Alcon") (NYSE:ALC) regarding its proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Broadwood, which owns 27.5% of STAAR's outstanding common stock, continues to urge its fellow shareholders to vote on its GREEN Proxy Card "AGAINST" the proposed transaction. Neal C. Bradsher, Broadwood Founder and President, said: "Today's press release and presentation from Alcon, which required STAAR's a
Alcon (SIX/NYSE:ALC), the global leader in eye care, today announced that it has filed an investor presentation in support of the proposed acquisition of STAAR Surgical Company (NASDAQ:STAA) with the U.S. Securities and Exchange Commission (SEC). Alcon plans to initiate outreach to STAAR stockholders and the presentation highlights key considerations for these discussions, including: The proposed merger represents a premium that significantly exceeds the median premium of comparable MedTech transactions and offers certain value to STAAR stockholders.1 The Broadwood Partners-led opposition campaign is an attempt at a "silent takeover" of STAAR Surgical. Broadwood has proposed removing ST
Questions Company's Adjournment and Postponement of the Special Meeting Without Substantive Explanation STAAR Should Heed the Strong Shareholder Opposition Already Expressed Through the Special Meeting Voting Process Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today released the following letter to the Board of Directors of STAAR after its decision to postpone STAAR's Special Meeting of Stockholders to vote on the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025. The text of the let
STAAR Special Meeting of Stockholders Postponed to December 3, 2025 STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL) announced that, in light of ongoing discussions with Alcon (SIX/NYSE:ALC), STAAR's Special Meeting of Stockholders in connection with STAAR's merger agreement with Alcon (the "Special Meeting"), which was previously adjourned until November 6, 2025 at 8:30 a.m. Pacific Time, has been postponed until December 3, 2025 at 8:30 a.m. Pacific Time. The new record date for the Special Meeting is the close of business on October 24, 2025. Stockholders who hold shares as of the record date will be eligible to vote at the postponed Specia
STAAR Should Not Delay the Inevitable and Should Let Shareholders Vote Company Should Not Commence a New "Go Shop" Period or Run a Rushed Sales Process Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today released the following letter to the Board of Directors of STAAR after the decision by STAAR Surgical and Alcon Inc. (SIX/NYSE:ALC) to adjourn STAAR's Special Meeting of Stockholders to vote on the proposed sale to Alcon on the terms announced on August 5, 2025. The text of the letter to the Board is as follows: Octo
Appalled that STAAR's Board Reneged on Its Promise to Let Shareholders Decide the Fate of the Proposed Transaction in a Timely Manner Urges STAAR to Give Up on Misbegotten Transaction and Refocus on Running the Business Intends to Seek Removal of STAAR Chair Elizabeth Yeu, CEO Stephen Farrell, and Compensation Committee Chair Arthur Butcher from the Board at a Special Meeting Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which owns 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today issued the following statement regarding the agreement between STAAR and Alcon Inc. ("Alcon") (NYSE:ALC) to postpone a share
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00
Jefferies downgraded STAAR Surgical from Buy to Hold
Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously
BTIG Research downgraded STAAR Surgical from Buy to Neutral
William Blair downgraded STAAR Surgical from Outperform to Mkt Perform
Morgan Stanley downgraded STAAR Surgical from Equal-Weight to Underweight and set a new price target of $37.00 from $50.00 previously
BTIG Research upgraded STAAR Surgical from Neutral to Buy and set a new price target of $46.00
Stifel upgraded STAAR Surgical from Hold to Buy and set a new price target of $50.00 from $30.00 previously
Needham downgraded STAAR Surgical from Buy to Hold
Morgan Stanley initiated coverage of STAAR Surgical with a rating of Equal-Weight and set a new price target of $35.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
Live Leadership Updates
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020. "Deborah has blended seamlessly with the leadership team, and we quickly realized that her deep knowledge of STAAR and her skills, abilities, and approach made her the perfect choice to be STAAR's next CFO," said the Company's CEO and Board member, Stephen Farrell. "In the last few months, Deborah has
Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to
New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. "Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry," said Aimee Weisner, Chair
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. "We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment institutions before founding her own firm a decade ago," said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical's Board of Directors. "We look forward to Lilian's contributions as a former institutional shar
This live feed shows all institutional transactions in real time.
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
Live finance-specific insights
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025. Third Quarter 2025 Financial Overview Net sales of $94.7 million up 6.9% Y/Y Net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment that was subject to extended payment terms, and which was paid in full during the third quarter 2025 pursuant to such payment terms (the "December China Shipment") Net sales excluding China of $38.9 million up 7.7% Y/Y Gross margin at 82.2% vs. 77.3% year ago due to the timing of the reco
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million
STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Date: Wednesday, August 6, 2025 Time: 4:30 p.m. ET Location: https://registrations.events/direct/IDX8578398 The live webcast, including an option to pre-register, can be accessed at the preceding link o
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we
China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 1Q 2025 Financial Results Webcast Date: Wednesday, May 7, 2025 Time: 5:15 p.m. ET Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=VN5Skdjp The live webcast, including an option to pre-register, can be accessed at the
Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended December 27, 2024. The Company moved up its earnings announcement and will hold a conference call and webcast today at 5:00 p.m. Eastern to discuss its financial results, oper
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. "Our industry-leading EVO ICL technology and market-building initiatives supported our ability to achieve double-digit year-over-year ICL sales growth globally in fiscal 2024, with the exception of China," said Tom Frinzi, Chair of the Board and CEO of STAAR Surgical. "The pervasive and well-documented economic conditions and lower levels of consumer confidenc